文献

J-GLOBAL ID：202002214676991087   整理番号：20A1088306

がん:ヒト新鮮腫瘍と凍結腫瘍を扱う単一細胞RNA-Seqおよび単一核RNA-Seqのツールボックス

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

著者 (95件)： SLYPER Michal (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  PORTER Caroline B. M. (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  ASHENBERG Orr (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WALDMAN Julia (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  DROKHLYANSKY Eugene (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  SMILLIE Christopher (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  SMITH-ROSARIO Gabriela (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  DIONNE Danielle (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  JANE-VALBUENA Judit (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  TICKLE Timothy L. (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  TSANKOV Alexander M. (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  JERBY-ARNON Livnat (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  KLUGHAMMER Johanna (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  ROSEN Yanay (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  GOULD Joshua (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  NGUYEN Lan (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  HOFREE Matan (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  ROZENBLATT-ROSEN Orit (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  REGEV Aviv (Klarman Cell Observatory, Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WAKIRO Isaac (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WU Jingyi (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  VIGNEAU Sebastien (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  NAPOLITANO Sara (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  SU Mei-Ju (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  GOHIL Satyen H. (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  COHEN Ofir (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  LI Bo (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WU Catherine J. (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  IZAR Benjamin (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  HAQ Rizwan (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  SUVA Mario L. (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  STOVER Elizabeth H. (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  COLLINS Natalie B. (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WAGLE Nikhil (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  ROTEM Asaf (Broad Inst. of Harvard and MIT, Cambridge, MA, USA) ,  WAKIRO Isaac (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  WU Jingyi (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  VIGNEAU Sebastien (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  NAPOLITANO Sara (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  SU Mei-Ju (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  GOHIL Satyen H. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  COHEN Ofir (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  WU Catherine J. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  IZAR Benjamin (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  HAQ Rizwan (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  HODI F. Stephen (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  YOON Charles H. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  STOVER Elizabeth H. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  MATULONIS Ursula A. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  WAGLE Nikhil (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  JOHNSON Bruce E. (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  ROTEM Asaf (Dep. of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  WAKIRO Isaac (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  WU Jingyi (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  VIGNEAU Sebastien (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  NAPOLITANO Sara (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  SU Mei-Ju (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  COHEN Ofir (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  IZAR Benjamin (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  WAGLE Nikhil (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  JOHNSON Bruce E. (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  ROTEM Asaf (Center for Cancer Precision Medicine of Dana-Farber Cancer Inst., Boston, MA, USA) ,  PATEL Anand G. (Dep. of Developmental Neurobiology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  KARLSTROM Asa (Dep. of Developmental Neurobiology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  BAKER Suzanne J. (Dep. of Developmental Neurobiology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  DYER Michael A. (Dep. of Developmental Neurobiology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  PATEL Anand G. (Dep. of Oncology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  GRITSCH Simon (Dep. of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  NOMURA Masashi (Dep. of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  SUVA Mario L. (Dep. of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  GRITSCH Simon (Center for Cancer Res., Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  NOMURA Masashi (Center for Cancer Res., Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  HATA Aaron N. (Center for Cancer Res., Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  SUVA Mario L. (Center for Cancer Res., Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  WAGHRAY Avinash (Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA) ,  TRAMONTOZZI Peter J. (Div. of Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA, USA) ,  BUENO Raphael (Div. of Thoracic Surgery, Brigham and Women’s Hospital, Boston, MA, USA) ,  LI Bo (Center for Immunology and Inflammatory Diseases, Div. of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  WU Catherine J. (Dep. of Internal Medicine, Brigham and Women’s Hospital, Boston, MA, USA) ,  WAGLE Nikhil (Dep. of Internal Medicine, Brigham and Women’s Hospital, Boston, MA, USA) ,  WU Catherine J. (Harvard Medical School, Boston, MA, USA) ,  WAGLE Nikhil (Harvard Medical School, Boston, MA, USA) ,  IZAR Benjamin (Lab. for Systems Pharmacology, Harvard Medical School, Boston, MA, USA) ,  IZAR Benjamin (Center for Immunology and Virology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  IZAR Benjamin (Ludwig Center for Cancer Res. at Harvard, Boston, MA, USA) ,  IZAR Benjamin (Melanoma Disease Center, Dana-Farber Cancer Inst., Boston, MA, USA) ,  HODI F. Stephen (Melanoma Disease Center, Dana-Farber Cancer Inst., Boston, MA, USA) ,  YOON Charles H. (Dep. of Surgical Oncology, Brigham and Women’s Hospital, Boston, MA, USA) ,  HATA Aaron N. (Dep. of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) ,  CLAY Michael R. (Dep. of Pathology, St Jude Children’s Res. Hospital, Memphis, TN, USA) ,  DYER Michael A. (Howard Hughes Medical Inst., Chevy Chase, MD, USA) ,  REGEV Aviv (Howard Hughes Medical Inst., Chevy Chase, MD, USA) ,  COLLINS Natalie B. (Dep. of Pediatric Oncology, Dana-Farber Cancer Inst., Boston, MA, USA) ,  COLLINS Natalie B. (Div. of Pediatric Hematology and Oncology, Boston Children’s Hospital, Boston, MA, USA) ,  REGEV Aviv (Koch Inst.e for Integrative Cancer Res., Dep. of Biology, Massachusetts Inst. of Technol., Cambridge, MA, USA)
資料名： Nature Medicine  (Nature Medicine)
巻： 26  号： 5  ページ： 792-802  発行年： 2020年05月 
JST資料番号： W0636A  ISSN： 1078-8956  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 単一細胞ゲノミクスは,腫瘍の生態系を描き出すのに不可欠である。単一細胞RNA-Seq(scRNA-Seq)は,新鮮な腫瘍から単離した細胞中のRNAのプロファイリングを行えるが,単一核RNA-Seq(snRNA-Seq)は凍結腫瘍や分離の難しい腫瘍のプロファイリングに必要である。どちらの方法も,多様な組織や腫瘍のタイプに合わせてカスタマイズする必要があり,それが試料に適用する際の障壁となっている。今回我々は,新鮮な,あるいは凍結後の腫瘍臨床試料を,それぞれscRNA-SeqとsnRNA-Seqを用いてプロファイリングするための体系的なツールボックスを開発し,さまざまな組織に由来し,試料特性が多様な8つの腫瘍タイプにわたる23症例からの40の標本から得た21万6490個の細胞と核を解析した。さらに,細胞と核の品質,回収率および細胞組成によって,プロトコルを評価した。マッチする試料からのscRNA-SeqとsnRNA-Seqでは同じ細胞タイプが回収されたが,割合は異なっていた。我々の研究は,他の腫瘍のためのツールボックスから引き出した手法を試験し,選択するための基準など,広範囲にわたる腫瘍の研究のための手引きとなるもので,腫瘍アトラスを描き出すための道を開くだろう。Copyright Nature Japan KK 2020

シソーラス用語： カスタム化 ,  回収率 ,  *RNA【核酸】 ,  *ヒト ,  snRNA ,  *凍結 ,  *腫瘍 ,  生態系
準シソーラス用語： アトラス ,  scRNA ,  プロファイリング ,  ゲノミクス ,  *ツールキット ,  核RNA ,  *単一細胞 , 【Automatic Indexing@JST】

分類 (3件)： 腫ようの化学・生化学・病理学  (GE02030N) ,  生物学的機能  (EB04020F) ,  細胞生理一般  (EF02010S)

タイトルに関連する用語 (9件)： がん ,  ヒト ,  新鮮 ,  腫瘍 ,  凍結 ,  単一細胞 ,  RNA-seq ,  核 ,  ツールボックス